Connecticut Cannabis: 72 Stores, 20% Capture, and the Progressive Tax Trap

Connecticut launched adult-use retail in January 2023 and two years later captures 20% of total cannabis demand. The structural problems are specific and measurable: a THC-based progressive tax system that penalizes the exact products consumers prefer, retail density that matches failed markets rather than successful ones, and a 30-mile drive to Massachusetts where the same ounce costs half the price. Market maturity is not the issue. Policy design is.

Market Overview

Connecticut legalized adult-use cannabis under Public Act 21-1 in June 2021. First adult-use retail sales launched January 14, 2023. The market is regulated by the Department of Consumer Protection.

Key metrics:

• 72 dispensaries statewide (40 hybrid, 31 adult-use only, 1 medical only)
• 2025 combined revenue: $290 million ($217.5M adult-use + $72.5M medical; CT open data)
• $7.69/g flower (pre-tax, December 2025; CT price data)
• 19–34% effective total tax burden depending on product potency
• ~20% estimated legal capture
• $4.03M revenue per store annually
• Adults 21+ population: 2.9 million

Flower Pricing

Connecticut's pricing data comes from the state's open data portal. At $7.69/g pre-tax, Connecticut sits above Maine's $6.38/g — but Maine achieves 100% capture. The difference is that Maine has no Massachusetts border. Connecticut does.

Connecticut's pre-tax price has declined 37.6% since launch ($12.32/g in January 2023 to $7.69/g). Price compression is happening. It just hasn't reached the level where legal cannabis is competitive with either the black market or Massachusetts — and the tax structure ensures it may never close the gap for the products consumers actually want.

The Progressive THC Tax: Connecticut's Unique Structural Problem

Connecticut is the only state in this dataset using a THC-based progressive excise tax rather than a flat percentage. The state charges per-milligram of THC content, which means higher-potency products — the exact products most consumers prefer — carry disproportionately higher tax burdens.

Tax structure:

• State sales tax: 6.35%
• Municipal sales tax: 3.0%
• THC excise (flower): $0.00625 per milligram of THC
• THC excise (vapes/concentrates): $0.009 per milligram
• THC excise (edibles): $0.0275 per milligram

What this produces in practice:

A consumer buying premium 30% THC flower pays a 33.7% total tax burden — comparable to Illinois's worst tier. The same consumer buying identical-potency flower in Massachusetts pays a flat 17–20% regardless of potency. For high-potency flower specifically, Connecticut charges $10.28/g all-in versus Massachusetts's $4.69–4.81/g — a 114–119% premium for the exact same product category.

This is the mechanism that makes Massachusetts border leakage so severe. It is not just that Connecticut is more expensive. It is that Connecticut taxes premium products at twice the rate of its neighbor, concentrating the price disadvantage precisely where consumer demand is highest.

Tax Structure

• THC-based progressive excise (see above)
• 6.35% state sales tax + 3.0% municipal sales tax
• Effective combined burden: 19–34% depending on potency
• Medical cannabis: taxed at lower rates

The 19–34% range makes Connecticut's average burden look comparable to Oregon or Massachusetts. The aggregate masks the problem: the progressive structure means heavy users, concentrate consumers, and premium flower buyers — the highest-value customers — face the worst relative pricing and thus the strongest incentive to shop elsewhere.

Total Addressable Market

Connecticut's adult population is approximately 2.9 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 2.9 million adults 21+
• 522,000 estimated regular consumers (18%)
• 190.5 million grams annual demand
• TAM at $7.69/g: ~$1.47 billion

Actual 2025 legal revenue of $290M against the $1.47B TAM implies approximately 20% capture, with an estimated $1.18 billion flowing through untaxed channels — black market dealers and Massachusetts dispensaries combined.

Revenue Trend

Growth is steady but capture has not materially improved. Maryland at the same two-year mark captures 49%. Connecticut at 20% after two years is not a timing problem — it is a structural problem.

The Massachusetts Border

Springfield, Massachusetts sits 30 miles north of Hartford. Massachusetts cannabis prices at $4.01/g pre-tax — 48% cheaper than Connecticut. For a Hartford-area consumer buying an ounce, the savings at a Massachusetts dispensary run approximately $155 per trip. Even accounting for the 2-hour round trip in time and vehicle costs, border shopping is economically rational for regular consumers throughout Hartford County.

The border leakage is not limited to the immediate boundary towns. The integrated Hartford-Springfield economic region means the effective border zone extends well into central Connecticut. Connecticut cannot solve this through price alone — closing a 48% gap is not achievable at current supply chain scale. The only partial remedies are tax reform (replacing the progressive structure with a flat rate) and density expansion (reducing consumer drive time to local dispensaries). Neither is a quick fix.

Dispensary Density

Connecticut's 2.5 per 100K density matches failed markets rather than successful ones. Massachusetts at 7.2 achieves full capture; Connecticut at 2.5 captures 20%. The $4.03M per-store revenue is nearly identical to Massachusetts's $4.07M — but Massachusetts has 5.6x more stores serving a larger population. Connecticut's per-store revenue reflects constrained access, not market efficiency.

Home Cultivation

Connecticut permits adults 21+ to cultivate up to 3 mature and 3 immature plants per person, with a household maximum of 12 plants grown indoors at the primary residence. At any price level where legal retail is uncompetitive, home grow participation remains in the 3-5% range observed across every other market. Connecticut's 20% capture rate is not a home grow problem. It is a price, density, and border competition problem.

What the CHS Literature Missed

Connecticut has a more developed CHS infrastructure than most states in this dataset. The Department of Consumer Protection maintains a dedicated CHS page published just nine months after adult-use launch — one of the few state cannabis regulators to do so. The page describes the syndrome clinically: causes, three phases, diagnostic criteria, and complications. It does not assert any prevalence rate. The criteria for who "might have CHS" specify daily use over a long period of time — framing the condition as a subset outcome, not a general consumer risk.

Hartford HealthCare, Connecticut's dominant hospital system, separately maintains a CHS page filed under its Neurogastroenterology and Motility Center — a subspecialty unit for gut-brain axis disorders. CHS is specialized enough to require a motility clinic rather than living in general ED guidance or primary care materials. That placement is consistent with a condition that is real and requires expert management when it presents, but not common enough to be handled routinely.

Both sources — the state regulator and the state's largest hospital system — engaged with CHS substantively without attaching a population-level prevalence figure. If CHS affected 17–33% of daily users as some clinical estimates suggest, Connecticut's 522,000 estimated regular consumers would include 44,000–86,000 active sufferers. A state that proactively built a CHS education page within nine months of launch would not omit a prevalence figure if one supported population-level concern. The omission from both regulatory and hospital sources is consistent with what population-level behavioral analysis shows about actual CHS frequency among regular consumers.

The Bottom Line

Connecticut's 20% capture after two years of adult-use sales is not a young market problem. The same variables that drive Illinois to 30% and New York to 8% are present here in a different configuration: insufficient retail density, a tax structure that uniquely penalizes the products consumers want most, and a neighbor state with a mature, low-price market 30 miles away. Price compression since launch has been real — 37.6% in two years — but from $12.32/g to $7.69/g still leaves Connecticut 92% more expensive than Massachusetts before the progressive tax compounds the gap further for premium products.

The Massachusetts border is a permanent competitive constraint. The progressive THC tax is a policy choice. The density gap is a licensing problem. Two of those three are addressable. Until they are, Connecticut will remain in the bottom quartile of adult-use market performance.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.